Sign In
Buy LIFE
aTyr Pharma Earnings Calls
| Release date | Aug 03, 2026 |
| EPS estimate | $0.0511 |
| EPS actual | - |
| Revenue estimate | 117.285M |
| Revenue actual | - |
| Expected change | +/- 9.40% |
| Release date | May 06, 2026 |
| EPS estimate | $0.460 |
| EPS actual | -$3.57 |
| EPS Surprise | -876.09% |
| Revenue estimate | 144.981M |
| Revenue actual | 193.099M |
| Revenue Surprise | 33.19% |
| Release date | Feb 25, 2026 |
| EPS estimate | $0.380 |
| EPS actual | $0.420 |
| EPS Surprise | 10.53% |
| Revenue estimate | 108.376M |
| Revenue actual | 110.077M |
| Revenue Surprise | 1.57% |
| Release date | Dec 05, 2025 |
| EPS estimate | -$0.100 |
| EPS actual | $0.290 |
| EPS Surprise | 390.00% |
| Revenue estimate | 190K |
| Revenue actual | 93.8M |
| Revenue Surprise | 49,268.42% |
Last 4 Quarters for aTyr Pharma
Below you can see how LIFE performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Dec 05, 2025 |
| Price on release | $1.90 |
| EPS estimate | -$0.100 |
| EPS actual | $0.290 |
| EPS surprise | 390.00% |
| Date | Price |
|---|---|
| Aug 27, 2024 | $1.90 |
| Aug 28, 2024 | $1.90 |
| Aug 29, 2024 | $1.90 |
| Aug 30, 2024 | $1.90 |
| Sep 03, 2024 | $1.90 |
| Jan 29, 2026 | $16.85 |
| Jan 30, 2026 | $15.05 |
| Feb 02, 2026 | $13.90 |
| Feb 03, 2026 | $12.73 |
| 4 days before | 0% |
| 4 days after | 570.00% |
| On release day | 786.84% |
| Change in period | 570.00% |
| Release date | Feb 25, 2026 |
| Price on release | $11.84 |
| EPS estimate | $0.380 |
| EPS actual | $0.420 |
| EPS surprise | 10.53% |
| Date | Price |
|---|---|
| Feb 19, 2026 | $10.89 |
| Feb 20, 2026 | $10.80 |
| Feb 23, 2026 | $11.00 |
| Feb 24, 2026 | $11.44 |
| Feb 25, 2026 | $11.84 |
| Feb 26, 2026 | $12.28 |
| Feb 27, 2026 | $12.35 |
| Mar 02, 2026 | $12.59 |
| Mar 03, 2026 | $13.16 |
| 4 days before | 8.72% |
| 4 days after | 11.15% |
| On release day | 3.72% |
| Change in period | 20.84% |
| Release date | May 06, 2026 |
| Price on release | $23.12 |
| EPS estimate | $0.460 |
| EPS actual | -$3.57 |
| EPS surprise | -876.09% |
| Date | Price |
|---|---|
| Apr 30, 2026 | $17.54 |
| May 01, 2026 | $18.65 |
| May 04, 2026 | $19.49 |
| May 05, 2026 | $21.05 |
| May 06, 2026 | $23.12 |
| May 07, 2026 | $30.59 |
| May 08, 2026 | $29.75 |
| May 11, 2026 | $29.78 |
| May 12, 2026 | $25.65 |
| 4 days before | 31.81% |
| 4 days after | 10.94% |
| On release day | 32.31% |
| Change in period | 46.24% |
| Release date | Aug 03, 2026 |
| Price on release | - |
| EPS estimate | $0.0511 |
| EPS actual | - |
| Date | Price |
|---|---|
| Jul 07, 2026 | $19.45 |
| Jul 08, 2026 | $18.90 |
| Jul 09, 2026 | $18.81 |
| Jul 10, 2026 | $20.09 |
| Jul 13, 2026 | $19.31 |
aTyr Pharma Earnings Call Transcript Summary of Q1 2026
Ethos Technologies reported an exceptional Q1 2026: revenue of $193 million (104% YoY growth), adjusted EBITDA of $34 million, and 88,373 policies activated (cumulative activated policies >600,000). The company highlighted a Rule of 40 score of 121 and continued strong unit economics as it scaled. Direct channel revenue grew 136% YoY driven by improvements across its vertically integrated stack (marketing, underwriting, funnel optimization) and a more than doubling of ad spend while maintaining ROAS. Third-party (agency) revenue grew 42% YoY as agencies recruited in 2025 began to ramp; newer agencies represented a double-digit percentage of third-party revenue. Product expansion momentum includes early traction for an accumulation IUL, two new whole life products with Banner Life, and a cancer product with Aflac; Ethos now offers 12 products across six carriers. Strategic partnerships were emphasized — notably a new Liberty Mutual licensing relationship to embed Ethos's underwriting engine and a ChatGPT-integrated user experience. The quarter included a one-time non-cash $16.5 million charge tied to updated agent compensation and clawback/persistency assumptions; management framed this as a positive signal of improving persistency and more precise estimates, but it increased reported agent compensation expense in the period. Liquidity: cash, cash equivalents and investments of $224 million; commission receivable of $345 million. Guidance: Q2 revenue guide $114–118 million and adjusted EBITDA $20–22 million; full-year 2026 revenue and adjusted EBITDA guidance were raised (management noted seasonal Q2 slowdown and a prudent forecasting approach). Key investor takeaways: materially accelerating revenue and strong profitability metrics, scalable and improving customer acquisition economics, expanding product and distribution footprint (including partnerships with large carriers), and a one-time accounting-related charge that reflects improving early persistency and more refined clawback assumptions.
